<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Consortium PSYCHIATRICUM</journal-id><journal-title-group><journal-title xml:lang="en">Consortium PSYCHIATRICUM</journal-title><trans-title-group xml:lang="ru"><trans-title>Consortium PSYCHIATRICUM</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2712-7672</issn><issn publication-format="electronic">2713-2919</issn><publisher><publisher-name xml:lang="en">Eco-Vector</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">15531</article-id><article-id pub-id-type="doi">10.17816/CP15531</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>PROTOCOL</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>ПРОТОКОЛ</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Motives for new psychoactive substances consumption among young adults in Uzbekistan: a qualitative study protocol</article-title><trans-title-group xml:lang="ru"><trans-title>Мотивы употребления новых психоактивных веществ молодыми людьми в Республике Узбекистан: протокол качественного исследования</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0001-9006-1733</contrib-id><name-alternatives><name xml:lang="en"><surname>Zakhidova</surname><given-names>Guzalkhon A.</given-names></name><name xml:lang="ru"><surname>Захидова</surname><given-names>Гузалхон Алижоновна</given-names></name></name-alternatives><address><country country="UZ">Uzbekistan</country></address><bio xml:lang="en"><p>PhD student; psychotherapist</p></bio><email>guzalya_zzz@mail.ru</email><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/><xref ref-type="aff" rid="aff3"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7952-9828</contrib-id><contrib-id contrib-id-type="scopus">57221802429</contrib-id><contrib-id contrib-id-type="researcherid">N-3225-2018</contrib-id><contrib-id contrib-id-type="spin">7134-4048</contrib-id><name-alternatives><name xml:lang="en"><surname>Pikirenia</surname><given-names>Uladzimir I.</given-names></name><name xml:lang="ru"><surname>Пикиреня</surname><given-names>Владимир Иванович</given-names></name></name-alternatives><address><country country="DE">Germany</country></address><bio xml:lang="en"><p>MD, Cand. Sci (Med.), Associate Professor at the Department of Psychiatry, narcology and Medical Psychology, postdoc</p></bio><email>guzalya_zzz@mail.ru</email><xref ref-type="aff" rid="aff2"/><xref ref-type="aff" rid="aff3"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4334-1601</contrib-id><contrib-id contrib-id-type="scopus">35773697500</contrib-id><contrib-id contrib-id-type="researcherid">I-8133-2013</contrib-id><contrib-id contrib-id-type="spin">7629-5309</contrib-id><name-alternatives><name xml:lang="en"><surname>Syunyakov</surname><given-names>Timur S.</given-names></name><name xml:lang="ru"><surname>Сюняков</surname><given-names>Тимур Сергеевич</given-names></name></name-alternatives><address><country country="UZ">Uzbekistan</country></address><bio xml:lang="en"><p>MD, Cand. Sci (Med.), Senior Researcher, Chief advisor on R&amp;D, Republican Specialized Scientific-Practical Medical Center of Narcology; Leading Expert (Coordinator on Statistical Data Analysis), International Centre for Education and Research in Neuropsychiatry</p></bio><email>guzalya_zzz@mail.ru</email><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff4"/><xref ref-type="aff" rid="aff5"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9099-316X</contrib-id><contrib-id contrib-id-type="scopus">56741402900</contrib-id><contrib-id contrib-id-type="researcherid">AAD-3806-2019</contrib-id><contrib-id contrib-id-type="spin">7582-3916</contrib-id><name-alternatives><name xml:lang="en"><surname>Prilutskaya</surname><given-names>Mariya V.</given-names></name><name xml:lang="ru"><surname>Прилуцкая</surname><given-names>Мария Валерьевна</given-names></name></name-alternatives><address><country country="DE">Germany</country></address><bio xml:lang="en"><p>Dr. Sci (Med.), Associate Professor</p></bio><email>guzalya_zzz@mail.ru</email><xref ref-type="aff" rid="aff2"/><xref ref-type="aff" rid="aff6"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Republican Specialized Scientific and Practical Medical Center for Mental Health</institution></aff><aff><institution xml:lang="ru">Республиканский специализированный научно-практический медицинский центр психического здоровья</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Frankfurt University of Applied Sciences</institution></aff><aff><institution xml:lang="ru">Франкфуртский университет прикладных наук</institution></aff></aff-alternatives><aff-alternatives id="aff3"><aff><institution xml:lang="en">Bukhara State Medical Institute</institution></aff><aff><institution xml:lang="ru">Бухарский государственный медицинский институт</institution></aff></aff-alternatives><aff-alternatives id="aff4"><aff><institution xml:lang="en">Mental-health Clinic No. 1 named after N.A. Alexeev</institution></aff><aff><institution xml:lang="ru">ГБУЗ «Психиатрическая клиническая больница № 1 им. Н.А. Алексеева Департамента здравоохранения города Москвы»</institution></aff></aff-alternatives><aff-alternatives id="aff5"><aff><institution xml:lang="en">Samara State Medical University</institution></aff><aff><institution xml:lang="ru">ФГБОУ ВО «Самарский государственный медицинский университет»</institution></aff></aff-alternatives><aff-alternatives id="aff6"><aff><institution xml:lang="en">Semey Medical University</institution></aff><aff><institution xml:lang="ru">Медицинский университет Семей</institution></aff></aff-alternatives><pub-date date-type="preprint" iso-8601-date="2025-03-12" publication-format="electronic"><day>12</day><month>03</month><year>2025</year></pub-date><pub-date date-type="pub" iso-8601-date="2025-04-01" publication-format="electronic"><day>01</day><month>04</month><year>2025</year></pub-date><volume>6</volume><issue>1</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>37</fpage><lpage>46</lpage><history><date date-type="received" iso-8601-date="2024-04-07"><day>07</day><month>04</month><year>2024</year></date><date date-type="accepted" iso-8601-date="2025-02-21"><day>21</day><month>02</month><year>2025</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2025, Zakhidova G.A., Pikirenia U.I., Syunyakov T.S., Prilutskaya M.V.</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2025, Захидова Г., Пикиреня В., Сюняков Т., Прилуцкая М.</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="en">Zakhidova G.A., Pikirenia U.I., Syunyakov T.S., Prilutskaya M.V.</copyright-holder><copyright-holder xml:lang="ru">Захидова Г., Пикиреня В., Сюняков Т., Прилуцкая М.</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by-nc-nd/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://consortium-psy.com/jour/article/view/15531">https://consortium-psy.com/jour/article/view/15531</self-uri><abstract xml:lang="en"><p><bold>BACKGROUND: </bold>New psychoactive substances (NPS) represent a global problem, especially among young people. In Central Asia, while the trafficking in NPS continues to grow, there remains a lack of data on the social, health and psychological consequences of their use.</p> <p><bold>AIM: </bold>To investigate the motives behind the NPS use among young people in the Republic of Uzbekistan, as well as the medical and social characteristics of this group.</p> <p><bold>METHODS:</bold> The study will include young people (18–35 years) who have used NPS in the preceeding 30 days (on the basis of self-reports) or are undergoing rehabilitation and plan to cease the NPS use within the next 12–18 months. Semi-structured interviews will reveal the reasons for NPS use, risk perception, stigma, barriers to seeking help, and the need for preventive and rehabilitation services. Interviews will take place at the Republican Mental Health Center and two specialized rehabilitation centers in Uzbekistan between November 2024 and the completion of enrollment (25–30 participants), but no later than May 2025. Additionally, a focus group of psychiatrists, psychotherapists, narcologists, and psychologists will evaluate the level of awareness amongst health care professionals as regards of NPS use and its prevalence, medical, and social implications.</p> <p><bold>EXPECTED RESULTS:</bold> The study will identify the key motives of NPS use, usage patterns, and social and medical barriers of help-seeking. Findings will contribute to the development of prevention and rehabilitation strategies, including digital communication platforms and interactive educational programs.</p> <p><bold>CONCLUSION: </bold>The study focuses on raising awareness about the consequences of NPS in the Republic of Uzbekistan. This is essential for developing effective public health prevention and rehabilitation programs.</p></abstract><trans-abstract xml:lang="ru"><p><bold>ВВЕДЕНИЕ: </bold>Новые психоактивные вещества (НПВ) представляют собой глобальную проблему, особенно среди молодежи. В Центральной Азии, на фоне увеличения трафика этих веществ, наблюдается нехватка данных о социальных, медицинских и психологических последствиях их употребления.</p> <p><bold>ЦЕЛЬ: </bold>Изучить мотивы употребления НПВ молодыми людьми в Республике Узбекистан, а также медико-социальные характеристики данной группы.</p> <p><bold>МЕТОДЫ:</bold> В исследование планируется включать молодых людей (18–35 лет), которые употребляли НПВ в последние 30 суток (по данным самоотчета) или проходят реабилитацию и планируют отказаться от употребления НПВ в течение последующих 12–18 месяцев. Для изучения мотивов употребления НПВ, восприятия риска, стигматизации, барьеров для обращения за помощью, потребностей в профилактике и реабилитации будут проведены полуструктурированные интервью. Интервью c потребителями НПВ пройдут в Республиканском центре психического здоровья и двух специализированных реабилитационных центрах Узбекистана в период с ноября 2024 года и до завершения набора участников (25–30 участников), но не позднее мая 2025 года. Осведомленность медицинских работников о распространенности и медико-социальных аспектах употребления НПВ изучат в фокус-группе с участием психиатров, психотерапевтов, наркологов и психологов.</p> <p><bold>ОЖИДАЕМЫЕ РЕЗУЛЬТАТЫ:</bold> По итогам исследования будут определены ключевые мотивы употребления НПВ, паттерны их использования, а также социальные и медицинские барьеры, препятствующие получению помощи. Также будут разработаны стратегии профилактики потребления НПВ и реабилитации потребителей, включая цифровые каналы коммуникации и интерактивные образовательные программы.</p> <p><bold>ЗАКЛЮЧЕНИЕ:</bold> Исследование нацелено на повышение осведомленности о последствиях распространения НПВ в Узбекистане. Его результаты будут способствовать разработке программ профилактики и реабилитации в системе общественного здравоохранения.</p></trans-abstract><kwd-group xml:lang="en"><kwd>new psychoactive substances</kwd><kwd>youth</kwd><kwd>study protocol</kwd><kwd>Uzbekistan</kwd><kwd>qualitative study</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>новые психоактивные вещества</kwd><kwd>молодежь</kwd><kwd>протокол исследования</kwd><kwd>Узбекистан</kwd><kwd>качественное исследование</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution xml:lang="en">Federal Ministry for Economic Cooperation and Development (BMZ)</institution></institution-wrap><institution-wrap><institution xml:lang="ru">Федеральное министерство экономического сотрудничества и развития</institution></institution-wrap></funding-source></award-group></funding-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Peacock A, Bruno R, Gisev N, et al. New psychoactive substances: challenges for drug surveillance, control, and public health responses. Lancet. 2019;394(10209):1668–1684. doi: 10.1016/S0140-6736(19)32231-7</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Prilutskaya M, Sadvakassova G, Altynbekov K, et al. Inpatient Care for People with New Psychoactive Substance use Disorders: A Trend Study. Journal of Health Development. 2024;55(1):50–58. doi: 10.32921/2225-9929-2024-1-55-50-58</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Altynbekov KS, Negai NA, Abetova AA. [Methodology and results of a national study on the consumption of psychoactive substances among young people in the Republic of Kazakhstan]. Vestnik KazNMU. 2021;(4):193–201. Russian.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Pisarska A, Deluca P, Demetrovics Z, et al. Novel psychoactive substances (NPS) – knowledge and experiences of drug users from Hungary, Poland, the UK and the USA. Neuropsychopharmacol Hung. 2019;21(4):152–163.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Benschop A, Urban R, Kapitany-Foveny M, et al. Why do people use new psychoactive substances? Development of a new measurement tool in six European countries. J Psychopharmacol. 2020;34(6):600–611. doi: 10.1177/0269881120904951</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Gittins R, Guirguis A, Schifano F, et al. Exploration of the Use of New Psychoactive Substances by Individuals in Treatment for Substance Misuse in the UK. Brain Sci. 2018;8(4):58. doi: 10.3390/brainsci8040058</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Coombs T, Ginige T, Van Calster P, et al. New Psychoactive Substances in the Homeless Population: A Cross-Sectional Study in the United Kingdom. Int J Ment Health Addict. 2023;22(4):2322–2237. doi: 10.1007/s11469-022-00988-7</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>O’Neill N. Mephedrone and Multiplicity: User Accounts of Effects and Harms. Contemp Drug Probl. 2014;41(3):417–444. doi: 10.1177/009145091404100307</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Assi S, Gulyamova N, Ibrahim K, et al. Profile, effects, and toxicity of novel psychoactive substances: A systematic review of quantitative studies. Hum Psychopharmacol. 2017;32(3). doi: 10.1002/hup.2607</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Higgins KM, O’Neill C, O’Hara L, et al. Evidence for public health on novel psychoactive substance use: a mixed-methods study. Public Health Res. 2019;7(14):1–150. doi: 10.3310/phr07140</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Papanti D, Schifano F, Botteon G, et al. “Spiceophrenia”: a systematic overview of “spice”-related psychopathological issues and a case report. Hum Psychopharmacol. 2013;28(4):379–389. doi: 10.1002/hup.2312</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Daziani G, Lo Faro AF, Montana V, et al. Synthetic Cathinones and Neurotoxicity Risks: A Systematic Review. Int J Mol Sci. 2023;24(7):6230. doi: 10.3390/ijms24076230</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Bilel S, Zamberletti E, Caffino L, et al. Cognitive dysfunction and impaired neuroplasticity following repeated exposure to the synthetic cannabinoid JWH-018 in male mice. Br J Pharmacol. 2023;180(21):2777–2801. doi: 10.1111/bph.16164</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Deluca P, Davey Z, Corazza O, et al. Identifying emerging trends in recreational drug use; outcomes from the Psychonaut Web Mapping Project. Prog Neuro-psychopharmacol Biol Psychiatry. 2012;39(2):221–226. doi: 10.1016/j.pnpbp.2012.07.011</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Chiappini S, Mosca A, Miuli A, et al. New Psychoactive Substances and Suicidality: A Systematic Review of the Current Literature. Medicina (Kaunas). 2021;57(6):580. doi: 10.3390/medicina57060580</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Wieczorek Ł, Dabrowska K, Bujalski M. Motives for using new psychoactive substances in three groups of Polish users: nightlife, marginalised and active on the In. Psychiatr Pol. 2022;56(3):453–470. doi: 10.12740/PP/131971</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Ricijaš N, Kranželić V, Leskovar L. Prevalence and the frequency of psychoactive substance consumption of youth in educational institutions — differences with regards to the type of institution and knowledge about psychoactive substances. Kriminologija &amp; Socijalna Integracija. 2019;27(1):35–67. doi: 10.31299/ksi.27.1.2</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Schijven EP, Didden R, Otten R, et al. Substance use among individuals with mild intellectual disability or borderline intellectual functioning in residential care: Examining the relationship between drinking motives and substance use. J Appl Res Intellect Disabil. 2019;32(4):871–878. doi: 10.1111/jar.12578</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Macgowan MJ, Engle B. Evidence for optimism: behavior therapies and motivational interviewing in adolescent substance abuse treatment. Child Adolesc Psychiatr Clin N Am. 2010;19(3):527–545. doi: 10.1016/j.chc.2010.03.006</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Agerwala SM, McCance-Katz EF. Integrating screening, brief intervention, and referral to treatment (SBIRT) into clinical practice settings: a brief review. J Psychoactive Drugs. 2012;44(4):307–317. doi: 10.1080/02791072.2012.720169</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Jatau AI, Sha’aban A, Gulma KA, et al. The Burden of Drug Abuse in Nigeria: A Scoping Review of Epidemiological Studies and Drug Laws. Public Health Rev. 2021;42:1603960. doi: 10.3389/phrs.2021.1603960</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Bandura A. Social foundations of thought and action: a social cognitive theory. Englewood Cliffs: Prentice-Hall; 1986.</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Syunyakov T, Khayredinova I, Ashurov Z. The Role of Family, Microsocial and Medical History in The Shaping of Trajectories of Complex Opioid and Cannabis Addiction: Results of Machine Learning Modeling. Personalized Psychiatry and Neurology. 2023;3(2):120–133. doi: 10.52667/2712-9179-2023-3-2-120-133</mixed-citation></ref></ref-list></back></article>
